[Skip to Navigation]
March 1973

Chemotherapy of Hodgkin's Disease: Maintenance Therapy vs No Maintenance After Remission Induction With Combination Chemotherapy

Author Affiliations


From the Southwest Cancer Chemotherapy Study Group, Houston. Dr. Luce is with the Mountain States Tumor Institute, Boise, Idaho; Dr. Frei is with the Children's Cancer Research Foundation, Boston; Dr. Gehan is with the University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston; Dr. Coltman is with the US Air Force Wilford Hall Hospital, San Antonio, Tex; Drs. Talley and Monto are with the Henry Ford Hospital, Detroit.

Arch Intern Med. 1973;131(3):391-395. doi:10.1001/archinte.1973.00320090081009

A therapeutic regimen (MOPP) that consisted of a combination of mechlorethamine hydrochloride, 3 to 6 mg/sq m intravenously, days 1 and 8, vincristine sulfate, 0.7 or 1.4 mg/sq m intravenously, days 1 and 8, procarbazine hydrochloride, 50 or 100 mg/sq m orally, every day for ten days, and prednisone, 40 mg/sq m orally, every day for ten days, was given every four weeks for 24 weeks to 164 patients with disseminated Hodgkin's disease. Patients in complete remission then received either no therapy or MOPP therapy every eight weeks. One hundred six patients achieved a complete remission (65%). The remission rate for stages IIIA, IIIB, and IVA ranged between 78% and 82%; for IVB it was 56%. At 95 weeks, 78% of the patients receiving maintenance therapy and only 50% of those not receiving maintenance were still in complete remission.